Cardiac Biomarkers Market
Report ID: SQMIG35A2951
Report ID: SQMIG35A2951
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35A2951 |
Region:
Global |
Published Date: November, 2024
Pages:
199
|Tables:
92
|Figures:
71
Cardiac Biomarkers Market size was valued at USD 11.95 Billion in 2024 and is poised to grow from USD 13.47 Billion in 2025 to USD 34.98 Billion by 2033, growing at a CAGR of 12.67% during the forecast period (2026–2033).
Cardiac biomarkers are the elements released in blood when the patient’s heart is stressed or damaged. They are necessary for managing and diagnosing different heart associated disorders like heart failures, heart attacks, and more. The cardiac biomarkers market is significantly driven by the growing incidences of heart diseases, increasing awareness regarding the benefits of early diagnosis, mounting demand for personalized medicines, and improvements in biomarker technologies. However, the market is restrained by costly advanced biomarker testing and lack of standardization, leading to variations in test results. Overall, the market is projected to continue progressing due to the growing number of innovations, higher emphasis on preventive healthcare, and rising healthcare expenditure.
Market snapshot - 2026-2033
Global Market Size
USD 10.61 Billion
Largest Segment
Laboratory Testing
Fastest Growth
Point of Care Testing
Growth Rate
12.67% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Cardiac Biomarkers Market is segmented by Product, Application, Location of Testing, and Region. Based on Product, the market is segmented into Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others. Based on Application, the market is segmented into Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others. Based on Location of Testing, the market is segmented into Laboratory Testing, Point of Care Testing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on type, the cardiac biomarkers market is segmented as troponin, CK-MB, myoglobin, BNP and NT-proBNP, and others. The troponin segment held a notable market share in 2023 and is projected to lead over the forecast period owing to high sensitivity and specificity. These tests are specific and highly sensitive for identifying myocardial injury, increasing their significance for diagnosing myocardial infarctions (heart attacks). Also, augmented levels of troponin are known as the gold standard for diagnosis of ACS and are used in clinics. Elevated troponin levels also show myocardial damage in early periods, allowing timely intervention.
Conversely, the BNP and NT-proBNP segment is anticipated to gain a significant market share over the coming years owing to better heart failure management. These biomarkers are essential for managing and diagnosing heart failures, a highly common heart condition. These biomarkers assist in differentiating such failures from other related symptoms. Also, they are associated with poor prediction in patients with heart failures, supporting risk stratification and managing treatment plans. These factors are contributing to the segment's growth.
Based on end-use, the market is segmented into laboratory testing, point of care testing. The laboratory testing segment registered for a significant market share in the past years and is expected to lead over the forecast period as well owing to its reliability and high accuracy. Laboratory tests use well-established techniques and devices that offer reliable and accurate outcomes for cardiac biomarkers. They adhere to the quality control measures and standardized protocols, and ensure precise and consistent diagnostic results, thus impacting the market growth.
Conversely, the point of care testing segment is projected to gain a notable market share over the estimated period owing to speedy results and convenience. Point of care testing offers immediate results, enabling treatment decisions and time diagnosis, which is vital for acute care settings and emergency cases. They also enhance accessibility and convenience for patients since they allow testing at the bedside. The said testing also simplifies workflows and reduces diagnosis time, improving clinical efficiency and better patient management.
To get detailed segments analysis, Request a Free Sample Report
Geographically, North America is the dominating region among others and is expected to lead over the forecast period owing to improved healthcare infrastructure with advanced diagnostic technologies and increased adoption of novel medical solutions. Also, the rising incidences of heart disorders in the region are rigorously demanding effective diagnostic solutions. Regional growth is further impacted by robust R&D along with strong network of clinical and academic research institutes, driving improvements in biomarker technologies. The leading players operating in the region include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Quidel Corporation, and more.
Asia-Pacific is the fastest-growing region in the global cardiac biomarkers market due to the speedy progress made by healthcare infrastructure and heavy investments in healthcare technologies. The market in the region is also driven by mounting cases of cardiovascular diseases due to diabetes, hypertension, and stress. Furthermore, affordability and enhancements in healthcare access are among the significant drivers of the market growth in the region. This, along with emerging market potential and growing geriatric population are driving the market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Focus on Preventive Healthcare and Early Diagnosis
Automation and Technological Integration
Challenges in Biomarker Reliability and Validation
Integration and Data Management Issues
Request Free Customization of this report to help us to meet your business objectives.
The global cardiac biomarkers market is a highly competitive global market driven by many international competitors. Prominent corporations with cutting-edge AI and ML technology are Google, IBM, Microsoft, and NVIDIA. To support a wide range of applications across industries, these industry experts concentrate on creating cutting-edge algorithms, scalable platforms, and reliable infrastructure. Rapid advances in technology, strategic alliances, and large expenditures on research and development define the competitive environment.
SkyQuest's ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the cardiac biomarkers market is being driven by factors like regional expansion and growth of developing economies, expanding use of biomarkers, and growing education and awareness on severe cardiac disorders among the public. However, the factors hampering the growth of the market include privacy and ethical concerns, growing competition from alternate diagnosing techniques, and integration issues. North America is predicted to lead the market owing to the strong regulatory environment, robust research and development, and growing cases of heart diseases. Yet, the market is poised to grow considerably in the coming years due to opportunities like the growing number of training and education programs, the growing number of strategic alliances, and the emphasis on preventive healthcare.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 11.95 Billion |
| Market size value in 2033 | USD 34.98 Billion |
| Growth Rate | 12.67% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cardiac Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cardiac Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cardiac Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cardiac Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
